HEALTHSOUTH

Third Quarter 2011 Earnings Call

Supplemental Slides

Forward-Looking Statements

The information contained in this presentation includes certain estimates, projections and other forward-looking information that reflect our current outlook, views and plans with respect to future events, including legislative and regulatory developments, strategy, capital expenditures, financial performance, and business model. These estimates, projections and other forward-looking information are based on assumptions that HealthSouth believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual events or results, and those differences may be material.

There can be no assurance that any estimates, projections or forward-looking information will be realized.

All such estimates, projections and forward-looking information speak only as of the date hereof. HealthSouth undertakes no duty to publicly update or revise the information contained herein.

You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the Form 10-K for the year ended December 31, 2010, our Form 10-Q for the quarters ended March 31, 2011, June 30, 2011, and September 30, 2011, when filed, and in other documents we previously filed with the SEC, many of which are beyond our control, that may cause actual events or results to differ materially from the views, beliefs and estimates expressed herein.

Note Regarding Presentation of Non-GAAP Financial Measures

The following presentation includes certain "non-GAAP financial measures" as defined in Regulation G under the Securities Exchange Act of 1934. Schedules are attached that reconcile the non-GAAP financial measures included in the following presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. Our Form 8-K, dated October 27, 2011, to which the following supplemental slides are attached as Exhibit 99.2, provides further explanation and disclosure regarding our use of non-GAAP financial measures and should be read in conjunction with these supplemental slides.

Table of Contents

HEALTHSOUTH

Q3 2011 Summary (Q3 2011 vs. Q3 2010)

- ✓ **Revenue growth of 8.0%**
  - — Inpatient revenue growth of 8.6%
    - ▪ Discharge growth 5.1%
      - • Strong same-store discharge growth of 4.0%
      - • Continued positive contribution from hospitals opened or acquired in the last 12 months

Location	# of Beds	Transaction	Date
Bristol, VA	25	De Novo	Q3 2010
Houston, TX	50	Acquired new IRF	Q3 2010

    - ▪ Revenue per discharge increase of 3.3%

- ✓ **Disciplined expense management and improved operating leverage**
  - — SWB as a percent of revenue decreased 110 bps.
  - — Hospital-related expenses as a percent of revenue decreased by 10 bps.

Q3 2011 Summary (Q3 2011 vs. Q3 2010) (cont.)

- ✓ **Adjusted EBITDA [1] for the quarter of $110.5 million reflects growth of 15.2%.**

- ✓ **Adjusted free cash flow [1] for the quarter of $32.4 million:**
  - — Benefited from higher Adjusted EBITDA
  - — Benefited from the absence of a swap payment ($10.6 million in Q3 2010)
  - — Offset by approx. $16 million for timing of interest payments
  - — Offset by approx. $17 million increase in accounts receivable
    - Medicare payment deferrals related to legal entity reorganizations
    - Increases resulting from revenue growth

Expect full-year adjusted free cash flow to be at least $210 million reflecting growth over full-year 2010 of at least 16%

- ✓ **Earnings per share [2] were negatively impacted by an $18.5 million, or $0.20 per share, increase in income tax expense mainly attributable to the release of the valuation allowance in Q4 2010 (see table on slide 11).**

(1) Reconciliation to GAAP provided on slides 31, 32, 34, and 37 - 38.

(2) Earnings per share from continuing operations attributable to HealthSouth

Q3 2011 Summary (Q3 2011 vs. Q3 2010) (cont.)

- ✓ **Completed the sale of five long-term acute care hospitals (LTCHs) for approx. $117.5 million.**
- ✓ **Additional capital structure enhancements**
  - — Completed the retirement of the10.75% senior notes due 2016
  - — Reduced total debt by $131 million during the quarter

Leverage ratio reduced to 2.9x (1)

- ✓ **TeamWorks Care Management implementation completed in all HealthSouth hospitals**
- ✓ **Clinical information system (CIS) implementation completed in second hospital**
  - — Pilot phase now complete
  - — System-wide rollout will begin in 2012

(1) Based on trailing four-quarter Adjusted EBITDA of $455.4 million; reconciliation to GAAP provided on slides 31, 32, 34, and 38.

High-Quality Care

HealthSouth Functional Outcomes Continue to Outpace Industry Average



FIM Gain
Change in Functional Independence Measurement (based on an 18 point assessment) from admission to discharge.

LOS Efficiency
Functional gain divided by length of stay.

* Average = Expected, Risk-adjusted

Source: UDSmr Database – On Demand Report: **Q3 2011 Report**

HEALTHSOUTH.

Revenues (Q3 2011 vs. Q3 2010)

(Millions)	Q3 2011	Q3 2010	Increase/ (Decrease)
Inpatient	$ 458.8	$ 422.6	8.6%
Outpatient and other	38.9	38.2	1.8%
Consolidated net operating	$ 497.7	$ 460.8	8.0%

(Actual Amounts)			
Discharges	29,350	27,931	5.1%
Net patient revenue / discharge	$15,632	$15,130	3.3%

✓ **Revenue growth of 8.0%**
- Inpatient revenue growth of 8.6%
  - Discharge growth of 5.1%
    - Strong same-store discharge growth of 4.0%
    - Continued positive contribution from hospitals opened or acquired in the last 12 months
  - Revenue per discharge increased 3.3%
    - Medicare (2.25%) and managed care price adjustments
    - Q3 2010 impacted by initial Medicare enrollment period (1) at hospitals opened in 2010
    - Improved patient outcomes
- Outpatient and other revenue benefited from $1.7 million in state provider taxes.

(1) We generally do not receive full reimbursement for the first 30 Medicare patients discharged from a new hospital.

HEALTHSOUTH

Expenses (Q3 2011 vs. Q3 2010)

(Millions)	Q3 2011	Q3 2010	Increase/ (Decrease)
Salaries and benefits	$ 245.0	$ 231.7	5.7%
Percent of net operating revenues	49.2%	50.3%	(110 bps)
EPOB (employees per occupied bed)	3.53	3.56	(0.8%)
Hospital-related expenses (other operating, supplies, occupancy, bad debts)	$ 112.6	$ 104.6	7.6%
Percent of net operating revenues	22.6%	22.7%	(10 bps)
General and administrative (excludes stock-based compensation)	$ 21.5	$ 21.5	0.0%
Percent of net operating revenues	4.3%	4.7%	(40 bps)

✓ **Disciplined expense management and improved operating leverage**

- SWB as a percent of revenue decreased 110 bps.
  - Q3 2010 results impacted by the ramping up of new hospitals.
- Hospital-related expenses as a percent of revenue decreased 10 bps.
  - Improved operating leverage offset by higher bad debt expense in Q3 2011

Adjusted EBITDA (1)

(Millions)	Q3 2011	Q3 2010	9 Months 2011	9 Months 2010
Net operating revenues	$ 497.7	$ 460.8	$ 1,508.8	$ 1,386.7
Operating expenses:				
Salaries and benefits (2)	(245.0)	(231.5)	(730.6)	(684.0)
Hospital-related expenses:				
Other operating expenses	(70.3)	(65.4)	(216.6)	(197.4)
Supplies	(24.7)	(24.1)	(76.7)	(73.3)
Occupancy Costs	(12.5)	(11.4)	(36.2)	(33.0)
Provision for doubtful accounts	(5.1)	(3.7)	(14.9)	(14.8)
	(112.6)	(104.6)	(344.4)	(318.5)
General and administrative expenses (3)	(21.5)	(21.5)	(66.3)	(66.7)
Equity in nonconsolidated affiliates	3.1	2.3	8.8	7.5
Other income	0.2	0.7	1.5	2.8
Noncontrolling interests (4)	(11.4)	(10.3)	(34.5)	(30.3)
Adjusted EBITDA	**$ 110.5**	**$ 95.9**	**$ 343.3**	**$ 297.5**

(1) Reconciliation to GAAP provided on slides 31, 32, 34, and 38.

	Q3 2011	Q3 2010	9 Months 2011	9 Months 2010
In arriving at Adjusted EBITDA, the following were excluded:				
(2) Retructuring charges	-	0.2	-	0.2
(3) Stock-based compensation expense	4.9	3.4	14.4	11.2
(4) Noncontrolling interests related to discontinued operations	0.1	0.2	1.1	0.2

Adjusted EBITDA Change

Q3	9 Months
+$14.6M	+$45.8M
+15.2%	+15.4%

- **Revenue growth driven by higher volumes and price**
- **Disciplined expense management and improved operating leverage**

HEALTHSOUTH

Earnings per Share

GAAP EPS Measure [1]

(In Millions, Except Per Share Data)	Q3 2011	Q3 2010	9 Months 2011	9 Months 2010
Adjusted EBITDA	$ 110.5	$ 95.9	$ 343.3	$ 297.5
Interest expense and amortization of debt discounts and fees	(26.3)	(30.8)	(96.3)	(91.4)
Depreciation and amortization	(19.5)	(18.4)	(58.6)	(53.7)
Stock-based compensation expense	(4.9)	(3.4)	(14.4)	(11.2)
Other, including non-cash loss on disposal of assets	(2.8)	(0.3)	(3.9)	(0.7)
	57.0	43.0	170.1	140.5
Certain nonrecurring expenses:				
Government, class action, and related settlements	-	(0.8)	10.6	(0.8)
Professional fees - accounting, tax, and legal	(4.0)	(5.2)	(16.2)	(13.8)
Loss on interest rate swaps	-	(9.0)	-	(13.0)
Loss on early extinguishment of debt	(12.7)	-	(38.8)	(0.4)
Pre-tax income	40.3	28.0	125.7	112.5
Income tax (expense) benefit [2]	(18.1) [3]	0.4 [4]	(21.9) [3] [5]	(0.7) [4]
Income from continuing operations [1]	$ 22.2	$ 28.4	$ 103.8 [5]	$ 111.8
Basic shares	93.3	92.8	93.2	92.7
Diluted shares	109.2	108.3	109.1	108.3
Basic earnings per share [6]	$ 0.17	$ 0.24	$ 0.90	$ 0.99
Diluted earnings per share [7]	$ 0.17	$ 0.24	$ 0.90	$ 0.99

Earnings per Share from Continuing Operations [1]

Q3 2011 impacted by:

- **$18.5 million, or $0.20 per share, increase in income tax expense primarily attributable to the release of the valuation allowance in Q4 2010**
- **$12.7 million loss on early extinguishment of debt in Q3 2011**
- **$9.0 million loss on interest rate swaps in Q3 2010**

(1) Income from continuing operations attributable to HealthSouth
(2) Actual tax provision recorded for the period
(3) Cash income taxes for the 3 and 9 months ended September 30, 2011 were $1.7 million and $5.9 million, respectively.
(4) During Q3 2010 and 9 months 2010, the Company maintained a valuation allowance against substantially all of its deferred tax assets. A substantial portion of the valuation allowance was released in Q4 2010.
(5) Includes an approx. $28 million, or $0.30 per share, benefit related to the Company's settlement with the IRS for tax years 2007 and 2008 and a reduction in unrecognized tax benefits due to the lapse of the statute of limitations for certain federal and state claims.
(6) The $6.5 million and $19.5 million dividends related to our convertible perpetual preferred stock in the 3 and 9 month periods ended September 30, 2011 and 2010, respectively, must be subtracted from income from continuing operations when calculating basic earnings per share.
(7) Diluted earnings per share on a GAAP basis are the same as basic earnings per share due to the antidilutive impact in each period presented.

Adjusted Free Cash Flow

Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow

	Q3		9 Months	
(Millions)	2011	2010	2011	2010
Net cash provided by operating activities	$ 53.9	$ 90.8	$ 210.8	$ 263.9
Impact of discontinued operations	(2.2)	(3.1)	(9.4)	(10.4)
Net cash provided by operating activities of continuing operations	51.7	87.7	201.4	253.5
Capital expenditures for maintenance	(12.8)	(11.8)	(35.1)	(24.6)
Net settlements on interest rate swaps	-	(10.6)	(10.9)	(33.7)
Dividends paid on convertible perpetual preferred stock	(6.5)	(6.5)	(19.5)	(19.5)
Distributions paid to noncontrolling interests of consolidated affiliates	(9.4)	(8.0)	(31.6)	(26.3)
Non-recurring items:				
Cash paid for professional fees - accounting, tax and legal	4.0	5.2	16.2	13.8
Net premium on bond issuance/repayment	8.9	-	22.8	-
Cash paid for government, class action and related settlements	-	-	7.7	0.8
Income tax refunds related to prior periods	(3.5)	(2.2)	(6.9)	(11.9)
Adjusted free cash flow	**$ 32.4**	**$ 53.8**	**$ 144.1**	**$ 152.1**

- **Adjusted free cash flow for the quarter was affected by:**
  - Benefited from higher Adjusted EBITDA
  - Benefited from the absence of a swap payment ($10.6 million Q3 2010)
  - Offset by approx. $16 million for the timing of interest payments
  - Offset by approx. $17 million increase in accounts receivable
    - Medicare payment deferrals related to legal entity reorganizations
    - Increases resulting from revenue growth

Expect full-year adjusted free cash flow to be at least $210 million reflecting growth over full-year 2010 of at least 16%

Debt and Liquidity

Debt Outstanding



Liquidity

	Sept. 30, 2011	Dec. 31, 2010
Cash Available	$ 47.7	$ 48.3
Revolver Total Line	$ 500.0	$ 500.0
Less:		
– Draws	(178.0)	(78.0)
– Letters of credit	(46.0)	(45.6)
Available	$ 276.0	$ 376.4
Total Liquidity	$ 323.7	$ 424.7

Credit Ratings

	S&P	Moodys
Corporate Rating	B+ Positive	B1 Positive
Revolver Rating	BB	Ba1
Senior Notes Rating	B+	B2

(1) Based on 2008 and trailing four-quarter Adjusted EBITDA of $322.6 million and $455.4 million, respectively; reconciliation to GAAP provided on slides 31 - 34 and 38.

HEALTHSOUTH.

Debt Profile

Capital Structure Enhancements:

- Completed the retirement of the 10.75% notes due 2016
- Reduced total debt by $131 million during the quarter
- Leverage ratio reduced to 2.9x (1)

Debt Profile:

- Additional debt pre-payment opportunities and flexible covenants (2)
- No near-term maturities and well-spaced debt maturities
- Limited exposure to higher interest rates

September 30 , 2011 (3)

($ in millions)



(1) Based on trailing four-quarter Adjusted EBITDA of $455.4 million; reconciliation to GAAP provided on slides 31, 32, 34, and 38.
(2) The credit agreement has a $200 million restricted payment basket for debt repayment and stock repurchases, which is subject to an annual grower basket equal to 50% of excess cash flow plus certain other amounts including net cash proceeds from certain equity issuances.
(3) Does not include $387.4 million of convertible perpetual preferred stock and capital leases and other note payables.

HEALTHSOUTH

Reinvesting Free Cash Flow

Priorities

Growth	• **Growth in core business** • Bed expansions • De novo hospitals • Hospital acquisitions • Acute care IRF unit acquisitions/consolidations • **Purchase properties under operating leases** • Lower capital cost • Greater control of property, CON and/or license

Potential Opportunities

Debt Reduction	• **Additional debt prepayment (revolver, term loan and senior notes)**
Shareholder Distribution	• **Share repurchase ($125 million authorization)** – Offset dilution from shares underlying convertible preferred shares (13.1 million shares), shares issued in settlement of securities litigation (5.0 million shares), and shares issued as a result of the Company's stock incentive plan • **Cash dividends (one time or regular)**

2011 Guidance – Adjusted EBITDA[1]

Original Guidance	Raised Guidance		
Feb. 17, 2011	**May 18, 2011**	**July 27, 2011**	**Oct. 27, 2011**
$440 million to $450 million (Inclusive of 12 months LTCH Adjusted EBITDA)	**$440 million to $450 million; (The high end of, or greater than)**	**$447 million to $453 million**	**$450 million to $455 million**

Guidance effectively raised by the 2011 expected LTCH Adjusted EBITDA ($17.5 million EBITDA in 2010)

Reflects 9.9% to 11.1% growth over 2010

Q4 2011 Considerations:

- ✓ Tough discharge volume comps (5.9% discharge growth in Q4 2010)
- ✓ Bad debt expense was $1.3 million, or 0.3% of revenue, in Q4 2010.
- ✓ Medicare pricing in Q4 2011 is expected to increase by approx. 1.6%.
- ✓ SWB benefited in Q4 2010 from a $3.3 million favorable adjustment related to workers' compensation.

[1] Reconciliation to GAAP provided on slides 31, 32, 34, and 38.

2011 Guidance – EPS

Basic Earnings per Share from Continuing Operations Attributable to HealthSouth (1)

$1.18 to $1.23

Diluted earnings per share on a GAAP basis are the same as basic earnings per share due to the antidilutive impact in the period.

Considerations:

- ✓ Includes $38.8 million, or $0.42 per share, loss (pre-tax) on early extinguishment of debt related to the Company's retirement of its 10.75% senior notes
- ✓ Includes an approx. $28 million, or $0.30 per share, benefit and assumes provision for income tax of 38% to 40% for Q4 2011; cash taxes expected to be $5 million to $8 million.
- ✓ $10.6 million, or $0.11 per share, gain (pre-tax) in government, class action, and related settlements
- ✓ The Company expects interest expense to be approx. $24 million in Q4 2011.
- ✓ The Adjusted EBITDA ($17.5 million in 2010) associated with the Company's six LTCHs has been reclassified to discontinued operations.
- ✓ Assumes a basic share count of 93.3 million shares

(1) Income from continuing operations attributable to HealthSouth

2011 Guidance – EPS

(In Millions, Except Per Share Data)	EPS Guidance Transition (LTCHs Reclassified to Disc. Ops.)					
	Prior EPS Measure [1]	GAAP EPS Measure [2]				
	Actual	Actual	Low	High	Low	High
	2010	2010	Original 2011		Revised 2011	
Adjusted EBITDA	**$ 409.6**	**$ 409.6**	**$ 440**	**$ 450**	**$ 450**	**$ 455**
Interest expense and amortization of debt discounts and fees	(125.6)	(125.6)	(138)		(120)	
Depreciation and amortization	(73.1)	(73.1)	(82)		(79)	
Stock-based compensation expense	(16.4)	(16.4)	(18)		(20)	
Other, including non-cash loss on disposal of assets	(1.6)	(1.6)	(4)		(5)	
	192.9	192.9	198	208	226	231
Certain Nonrecurring Expenses:						
Government, class action and related settlements	-	(1.1)	-		11	
Professional fees - accounting, tax and legal	-	(17.2)	(14)		(18)	
Loss on interest rate swaps	-	(13.3)	-		-	
Loss on early extinguishment of debt	(12.3)	(12.3)	-		(39)	
Pre-tax income	**180.6**	**149.0**	**184**	**194**	**180**	**185**
Income tax	(8.0) [3]	740.8 [4]	(74)	(78)	(44) [5]	(44) [5]
Income from continuing operations	**$ 172.6** [1]	**$ 889.8** [2]	**$ 110** [2]	**$ 116** [2]	**$ 136** [2][5]	**$ 141** [2][5]
Basic shares [6]	92.8	92.8	93.2	93.2	93.3	93.3
Diluted shares	108.5	108.5	109.4	109.4	109.5	109.5
Earnings per share	**$ 1.59** [1]	**$ 8.20** [2]	**$ 1.01** [2]	**$1.06** [2]	**$1.18** [2]	**$1.23** [2]

(1) Adjusted income from continuing operations. This non-GAAP measure was part of our historical guidance and has been recast to reflect the 6 LTCHs moving to discontinued operations. A reconciliation of adjusted income from continuing operations to the corresponding GAAP measure can be found on slides 35 - 36.
(2) Income from continuing operations attributable to HealthSouth (reclassified for the 6 LTCHs moving to discontinued operations)
(3) Current period amounts in income tax provision; see slides 35 – 36.
(4) Total income tax provision for full-year 2010, including the reversal of a substantial portion of the Company's valuation allowance against deferred tax assets.
(5) Includes an approx. $28 million, or $0.30 per share, benefit related to the Company's settlement with the IRS for tax years 2007 and 2008, and a reduction in unrecognized tax benefits due to the lapse of the statute of limitations for certain federal and state claims; assumes 38% to 40% effective tax rate for Q4 2011.
(6) The dividends related to our convertible perpetual preferred stock must be subtracted from income from continuing operations when calculating basic earnings per share.

Adjusted Free Cash Flow [1] Considerations



HealthSouth's GAAP income statement will be affected by a number of items that <u>will not affect</u> adjusted free cash flow:

- Normalized GAAP tax rate resulting from the valuation allowance reversal in Q4 2010.
- Loss on early extinguishment of debt

Expect full-year adjusted free cash flow to be at least $210 million reflecting growth over full-year 2010 of at least 16%

- **Items that <u>will affect</u> Adjusted Free Cash Flow in 2011**:
  - \+ Cash settlements for interest rate swaps will be $33.8 million lower in 2011.
  - \+ Lower interest expense in the second half of 2011:
    - Retirement of the 10.75% senior notes.
  - – Maintenance capital expenditures are estimated to be approx. $10 to $15 million higher in 2011 than 2010.
- The Company paid approx. $23 million cash in net call premiums to retire the 10.75% senior notes. This use of cash is excluded from adjusted free cash flow.

(1) Reconciliation to GAAP provided on slide 37.

HEALTHSOUTH

Appendix

Business Model and Potential Medicare Reductions

Business Model
- **Adjusted EBITDA CAGR: 5-8% (1)**
- **Adjusted Free Cash Flow CAGR: 12-17% (1)**

Strategy	2010	2011	2012	2013
Delevering (2)				
Growth				
Key Operational Initiatives				

Scenario *	Estimated Impact to HealthSouth	Reaffirm Business Model
Special Committee actions mirror President's Fiscal Commission (Simpson Bowles)	(million) Net Operating Revenues ($4.0) Adjusted EBITDA ($7.0) Note: Impact based on 2012	YES
Special Committee fails and 2% sequestration is triggered	(million) Net Operating Revenues ($32.0) Adjusted EBITDA ($32.0) Note: Effective 10/1/12; impact is shown for 2013	YES
President's Proposal and/or other proposals that may be brought forward	(million) Insufficient detail to determine the total impact of President's proposal** and/or other proposals that may be enacted.	TBD

* Above estimates assume no mitigating action by HealthSouth.
** The Company previously estimated the impact of increasing the IRF compliance threshold to 75% would be approx. $42 million in revenue and approx. $26 million in Adjusted EBITDA.

(1) Reconciliation to GAAP provided on slides 31 - 38.
(2) Exclusive of any E&Y recovery.

HEALTHSOUTH

Income Tax Considerations

GAAP Considerations:

- As of 9/30/11, the Company had an ending balance of approx. $1.3 billion in federal NOLs and a remaining valuation allowance of approx. $105 million, primarily related to state NOLs.
- Expect effective tax rate of approx. 40% going forward

Future Cash Tax Payments:

- The Company expects to pay approx. $5 million to $8 million per year of income tax.
- The Company does not expect to pay significant federal income taxes for up to 7 years.
- HealthSouth is not currently subject to an annual use limitation ("AUL") under Internal Revenue Code Section 382 ("Section 382"). A "change of ownership," as defined by Section 382, would subject us to an AUL, which is equal to the market capitalization of the Company at the time of the "change of ownership" multiplied by the long-term tax exempt rate.

Our Historic Discharge Growth vs. Industry

HealthSouth's volume growth has outpaced competitors'

Same Store HealthSouth vs. Industry



Quarterly Discharge Growth



	2008	2009	2010	2011
Yearly Discharge Growth	6.9%	5.6%	3.1%	

- TeamWorks = standardized and enhanced sales & marketing
- Bed additions will help facilitate continued organic growth

(1) Data provided by UDSMR, a data gathering and analysis organization for the rehabilitation industry; represents ~ 65-70% of industry, including HealthSouth sites.
(2) Includes consolidated HealthSouth inpatient rehabilitation hospitals classified as same store during that time period.

HEALTHSOUTH

Debt Schedule

(Millions) Corporate	Credit Rating S&P B+	Credit Rating Moody B1	Sept. 30, 2011	Dec. 31, 2010	Change in Debt vs. YE 2010
Advances under $500 million revolving credit facility, May 2016 - 3 Month LIBOR +225bps	BB	Ba1	$ 178.0	$ 78.0	$ 100.0
Term loan facility, May 2016 - 3 Month LIBOR +225bps	BB	Ba1	98.8	-	98.8
Bonds Payable:					
10.75% Senior Notes due 2016	B+	B2	-	495.5	(495.5)
7.25% Senior Notes due 2018	B+	B2	336.8	275.0	61.8
8.125% Senior Notes due 2020	B+	B2	285.7	285.5	0.2
7.75% Senior Notes due 2022	B+	B2	312.0	250.0	62.0
Other bonds payable			1.5	1.8	(0.3)
Other notes payable			35.9	36.4	(0.5)
Capital lease obligations			79.0	89.1	(10.1)
Long-term debt			**$ 1,327.7**	**$ 1,511.3**	**$ (183.6)**
Debt to Adjusted EBITDA [(1)]			**2.9x**	**3.7x**	

(1) Based on 4 quarter trailing and 2010 Adjusted EBITDA of $455.4 million and $409.6 million, respectively; reconciliation to GAAP provided on slides 31, 32, 34, and 38.

HEALTHSOUTH

Revenues & Expenses (9 Months)

	9 Months		Increase/
Revenues (millions)	**2011**	**2010**	**(Decrease)**
Inpatient	$ 1,386.3	$ 1,270.4	9.1%
Outpatient and other	122.5	116.3	5.3%
Consolidated net operating	$ 1,508.8	$ 1,386.7	8.8%
(Actual Amounts)			
Discharges	88,288	83,052	6.3%
Net patient revenue / discharge	$ 15,702	$ 15,296	2.7%
Expenses (millions)			
Salaries and benefits	$ 730.6	$ 684.2	6.8%
Percent of net operating revenues	48.4%	49.3%	(90 bps)
EPOB (employees per occupied bed)	3.47	3.48	(0.3%)
Hospital-related expenses	$ 344.4	$ 318.5	8.1%
(other operating, supplies, occupancy, bad debts)			
Percent of net operating revenues	22.8%	23.0%	(20 bps)
General and administrative	$ 66.3	$ 66.7	(0.6%)
(excludes stock-based compensation)			
Percent of net operating revenues	4.4%	4.8%	(40 bps)

Revenues & Expenses (Sequential)

Revenues (millions)	Q3 2011	Q2 2011	Increase/ (Decrease)
Inpatient	$ 458.8	$ 465.4	(1.4%)
Outpatient and other	38.9	39.7	(2.0%)
Consolidated net operating	$ 497.7	$ 505.1	(1.5%)
(Actual Amounts)			
Discharges	29,350	29,811	(1.5%)
Net patient revenue / discharge	$ 15,632	$ 15,612	0.1%
Expenses (millions)			
Salaries and benefits	$ 245.0	$ 241.6	1.4%
Percent of net operating revenues	49.2%	47.8%	140 bps
EPOB (employees per occupied bed)	3.53	3.47	1.7%
Hospital-related expenses	$ 112.6	$ 118.7	(5.1%)
(other operating, supplies, occupancy, bad debts)			
Percent of net operating revenues	22.6%	23.5%	(90 bps)
General and administrative	$ 21.5	$ 22.1	(2.7%)
(excludes stock-based compensation)			
Percent of net operating revenues	4.3%	4.4%	(10 bps)

Payment Sources (Percent of Revenue)

	Q3		9 Months		Full Year
	2011	2010	2011	2010	2010
Medicare	72.0%	70.2%	71.8%	70.2%	70.5%
Medicaid	1.6%	1.8%	1.7%	1.8%	1.8%
Workers' compensation	1.6%	1.6%	1.7%	1.6%	1.6%
Managed care and other discount plans (1)	20.0%	21.5%	19.8%	21.5%	21.3%
Other third-party payors	1.9%	2.3%	2.0%	2.3%	2.3%
Patients	1.3%	1.4%	1.2%	1.3%	1.3%
Other income	1.6%	1.2%	1.8%	1.3%	1.2%
Total	100.0%	100.0%	100.0%	100.0%	100.0%

(1) Managed Medicare revenues represent ~ 7%, 8%, 7%, 8%, and 8% of total revenues for Q3 2011, Q3 2010, 9 Months 2011, and 9 Months 2010, Full Year 2010, respectively, and are included in "Managed care and other discount plans."

Operational and Labor Metrics [1]

	Q3 2011	Q2 2011	Q1 2011	Q4 2010	Q3 2010	Q2 2010	Q1 2010	9 Months 2011	9 Months 2010	Full Year 2010
						(In Millions)				
Net patient revenue-inpatient	$ 458.8	$ 465.4	$ 462.1	$ 452.3	$ 422.6	$ 427.6	$ 420.2	$ 1,386.3	$ 1,270.4	$ 1,722.7
Net patient revenue-outpatient and other revenues	38.9	39.7	43.9	38.6	38.2	39.7	38.4	122.5	116.3	154.9
Net operating revenues	$ 497.7	$ 505.1	$ 506.0	$ 490.9	$ 460.8	$ 467.3	$ 458.6	$ 1,508.8	$ 1,386.7	$ 1,877.6
						(Actual Amounts)				
Discharges [2]	29,350	29,811	29,127	29,462	27,931	28,098	27,023	88,288	83,052	112,514
Outpatient visits	236,969	244,647	236,761	244,719	253,837	260,374	250,467	718,377	764,678	1,009,397
Average length of stay	13.4	13.4	13.8	13.4	13.8	13.7	14.2	13.5	13.9	13.8
Occupancy %	67.2%	69.0%	70.2%	67.8%	66.0%	67.8%	69.3%	68.6%	66.7%	67.0%
# of licensed beds	6,376	6,356	6,350	6,331	6,331	6,250	6,129	6,376	6,331	6,331
Occupied beds	4,285	4,386	4,458	4,292	4,178	4,238	4,247	4,374	4,223	4,242
Full-time equivalents (FTEs) [3]	15,081	15,150	15,044	14,958	14,785	14,628	14,450	15,092	14,621	14,705
Contract labor	60	76	89	84	71	84	74	75	76	79
Total FTE and contract labor	15,141	15,226	15,133	15,042	14,856	14,712	14,524	15,167	14,697	14,784
EPOB [4]	3.53	3.47	3.39	3.50	3.56	3.47	3.42	3.47	3.48	3.49

(1) Numbers have been reclassified to reflect current continuing operations.

(2) Represents discharges from HealthSouth's 94 consolidated hospitals in Q3 2011, Q2 2011, Q1 2011, Q4 2010 and Q3 2010, 92 consolidated hospitals in Q2 2010, and 90 consolidated hospitals prior to Q2 2010.

(3) Excludes approximately 400 full-time equivalents, who are considered part of corporate overhead with their salaries and benefits included in general and administrative expenses in the Company's consolidated statements of operations. Full-time equivalents included in the above table represent HealthSouth employees who participate in or support the operations of the Company's hospitals.

(4) Employees per occupied bed, or "EPOB," is calculated by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by the Company's occupancy percentage.

Outstanding Share Summary and Warrant Information

(Millions)

	Weighted Average for the Period					
	Q3 2011	Q3 2010	9 Months 2011	9 Months 2010	FY 2010	FY 2009
Basic Shares outstanding (1) (2)	93.3	92.8	93.2	92.7	92.8	88.8
Diluted Shares outstanding (1) (2) (3)	109.2	108.3	109.1	108.3	108.5	103.3

	End of Period					
	Q3 2011	Q3 2010	9 Months 2011	9 Months 2010	FY 2010	FY 2009
Basic Shares outstanding (1) (2)	93.3	92.8	93.3	92.8	92.8	92.6
Diluted Shares outstanding (1) (2) (3)	109.2	108.3	109.3	108.3	108.5	107.1

Notes:

(1) Does not include 2.0 million warrants issued in connection with a January 2004 loan repaid to Credit Suisse First Boston. In connection with this transaction, we issued warrants to the lender to purchase two million shares of our common stock. Each warrant has a term of ten years from the date of issuance (expire January 16, 2014) and an exercise price of $32.50 per share. The warrants were not assumed exercised for dilutive shares outstanding because they were antidilutive in the periods presented.

(2) The agreement to settle our class action securities litigation received final court approval in January 2007. These shares of common stock and warrants were issued on September 30, 2009. The 5.0 million of common shares are now included in the outstanding shares. The warrants to purchase approx. 8.2 million shares of common stock at a strike price of $41.40 (expire January 17, 2017) were not assumed exercised for the dilutive shares outstanding because they are anti-dilutive in the periods presented.

(3) The difference between the basic and diluted shares outstanding is primarily related to our convertible perpetual preferred stock (13.1 million shares). The preferred stock is convertible, at the option of the holder, at any time into shares of common stock at an initial conversion price of $30.50 per share, which is equal to an initial conversion rate of approximately 32.7869 shares of common stock per share of preferred stock, subject to a specified adjustment. On or after July 20, 2011, we may cause the shares of preferred stock to be automatically converted into shares of our common stock at the conversion rate then in effect if the closing price of our common stock for 20 trading days within a period of 30 consecutive trading days ending on the trading day before the date we give the notice of forced conversion exceeds 150% of the conversion price of the preferred stock.

Adjusted EBITDA (1) History

(Millions)	Q3 2011	Q2 2011	Q1 2011	Q4 2010	Q3 2010	Q2 2010	Q1 2010	9 Months 2011	9 Months 2010	Full Year 2010
Net operating revenues	$ 497.7	$ 505.1	$ 506.0	$ 490.9	$ 460.8	$ 467.3	$ 458.6	$ 1,508.8	$ 1,386.7	$ 1,877.6
Operating expenses:										
Salaries and benefits (2)	(245.0)	(241.6)	(244.0)	(237.5)	(231.5)	(226.2)	(226.3)	(730.6)	(684.0)	(921.5)
Hospital-related expenses:										
Other operating expenses	(70.3)	(75.4)	(70.9)	(72.1)	(65.4)	(70.8)	(61.2)	(216.6)	(197.4)	(269.5)
Supplies	(24.7)	(26.2)	(25.8)	(26.1)	(24.1)	(25.0)	(24.2)	(76.7)	(73.3)	(99.4)
Occupancy Costs	(12.5)	(12.1)	(11.6)	(11.9)	(11.4)	(10.7)	(10.9)	(36.2)	(33.0)	(44.9)
Provision for doubtful accounts	(5.1)	(5.0)	(4.8)	(1.6)	(3.7)	(5.2)	(5.9)	(14.9)	(14.8)	(16.4)
	(112.6)	(118.7)	(113.1)	(111.7)	(104.6)	(111.7)	(102.2)	(344.4)	(318.5)	(430.2)
General and administrative expenses (3)	(21.5)	(22.1)	(22.7)	(23.1)	(21.5)	(22.7)	(22.5)	(66.3)	(66.7)	(89.8)
Equity in nonconsolidated affiliates	3.1	3.2	2.5	2.6	2.3	2.6	2.6	8.8	7.5	10.1
Other income	0.2	0.7	0.6	1.5	0.7	1.4	0.7	1.5	2.8	4.3
Noncontrolling interests (4)	(11.4)	(11.3)	(11.8)	(10.6)	(10.3)	(10.3)	(9.7)	(34.5)	(30.3)	(40.9)
Adjusted EBITDA	**$ 110.5**	**$ 115.3**	**$ 117.5**	**$ 112.1**	**$ 95.9**	**$ 100.4**	**$ 101.2**	**$ 343.3**	**$ 297.5**	**$ 409.6**

(1) Reconciliation to GAAP provided on slides 31, 32, 34, and 38.

	Q3 2011	Q2 2011	Q1 2011	Q4 2010	Q3 2010	Q2 2010	Q1 2010	9 Months 2011	9 Months 2010	Full Year 2010
In arriving at Adjusted EBITDA, the following were excluded:										
(2) Restructuring charges	$ -	$ -	$ -	$ -	$ 0.2	$ -	$ -	$ -	$ 0.2	$ 0.2
(3) Stock-based compensation expense	4.9	5.3	4.2	5.2	3.4	4.0	3.8	14.4	11.2	16.4
(4) Noncontrolling interests related to discontinued operations	0.1	0.9	0.1	(0.1)	0.2	0.1	(0.1)	1.1	0.2	0.1

HEALTHSOUTH

Reconciliation of Net Income to Adjusted EBITDA (1)(3)

(in millions, except per share data)	2011 Q1 Total	Q1 Per Share	Q2 Total	Q2 Per Share	Q3 Total	Q3 Per Share	9 Months Total	9 Months Per Share
Net income	$ 91.5		$ 32.3		$ 68.3		$ 192.1	
Income from disc ops, net of tax, attributable to HealthSouth	(17.6)		(2.5)		(34.8)		(54.9)	
Net income attributable to noncontrolling interests	(11.7)		(10.4)		(11.3)		(33.4)	
Income from continuing operations attributable to HealthSouth (2)	62.2	$ 0.57	19.4	$ 0.14	22.2	$ 0.17	103.8	$ 0.90
Gov't, class action, and related settlements	-		(10.6)		-		(10.6)	
Pro fees - acct, tax, and legal	3.8		8.4		4.0		16.2	
Provision for income tax (benefit) expense	(7.4)		11.2		18.1		21.9	
Interest expense and amortization of debt discounts and fees	35.1		34.9		26.3		96.3	
Depreciation and amortization	19.5		19.6		19.5		58.6	
Loss on early extinguishment of debt	-		26.1		12.7		38.8	
Net noncash loss on disposal of assets	0.1		1.0		2.8		3.9	
Stock-based compensation expense	4.2		5.3		4.9		14.4	
Adjusted EBITDA (1)(3)	$ 117.5		$ 115.3		$ 110.5		$ 343.3	
Weighted average common shares outstanding:								
Basic (4)		93.1		93.3		93.3		93.2
Diluted		109.0		109.5		109.2		109.1

(1) (2) (3) (4) – Notes on page 34

Reconciliation of Net Income to Adjusted EBITDA (1)(3)

	2010									
	Q1		Q2		Q3		Q4		Full Year	
(in millions, except per share data)	Total	Per Share	Total	Per Share	Total	Per Share	Total	Per Share	Total	Per Share
Net income	$ 50.5		$ 57.5		$ 41.9		$ 789.9		$ 939.8	
Income from disc ops, net of tax, attributable to HealthSouth	(1.2)		(3.4)		(3.4)		(1.2)		(9.2)	
Net income attributable to noncontrolling interests	(9.8)		(10.2)		(10.1)		(10.7)		(40.8)	
Income from continuing operations attributable to HealthSouth [2]	39.5	$ 0.36	43.9	$ 0.40	28.4	$ 0.24	778.0	$ 7.15	889.8	$ 8.20
Gov't, class action, and related settlements	-		-		0.8		0.3		1.1	
Pro fees - acct, tax, and legal	2.9		5.7		5.2		3.4		17.2	
Loss (gain) on interest rate swaps	4.3		(0.3)		9.0		0.3		13.3	
Provision for income tax expense (benefit)	2.4		(1.3)		(0.4)		(741.5)		(740.8)	
Interest expense and amortization of debt discounts and fees	30.5		30.1		30.8		34.2		125.6	
Depreciation and amortization	17.5		17.8		18.4		19.4		73.1	
Net noncash loss on disposal of assets	-		0.4		0.1		0.9		1.4	
Loss on early extinguishment of debt	0.3		0.1		-		11.9		12.3	
Stock-based compensation expense	3.8		4.0		3.4		5.2		16.4	
Other	-		-		0.2		-		0.2	
Adjusted EBITDA [1][3]	$ 101.2		$ 100.4		$ 95.9		$ 112.1		$ 409.6	
Weighted average common shares outstanding:										
Basic [4]		92.7		92.8		92.8		92.8		92.8
Diluted		108.0		108.2		108.3		108.8		108.5

(1) (2) (3) (4) – Notes on page 34.

Reconciliation of Net Income to Adjusted EBITDA (1) (3)

	Full Year			
	2008		2009	
(in millions, except per share data)	Total	Per Share	Total	Per Share
Net income	$ 281.8		$ 128.8	
Income from disc ops, net of tax, attributable to HealthSouth	(32.5)		(17.7)	
Net income attributable to noncontrolling interests	(29.4)		(34.0)	
Income from continuing operations attributable to HealthSouth [2]	219.9	$ 2.28	77.1	$ 0.57
Gain on UBS Settlement	(121.3)		-	
Gov't, class action, and related settlements	(67.2)		36.7	
Pro fees - acct, tax, and legal	44.4		8.8	
Loss on interest rate swaps	55.7		19.6	
Provision for income tax benefit	(69.1)		(2.9)	
Interest expense and amortization of debt discounts and fees	159.3		125.7	
Depreciation and amortization	78.9		67.6	
Other adjustments per the Company's Credit Agreement:				
Impairment charges, including investments	2.4		1.4	
Net noncash loss on disposal of assets	2.0		3.4	
Loss on early extinguishment of debt	5.9		12.5	
Stock-based compensation expense	11.7		13.4	
Other	-		0.4	
Adjusted EBITDA [1][3]	$ 322.6		$ 363.7	
Weighted average common shares outstanding:				
Basic [4]		83.0		88.8
Diluted		96.4		103.3

(1) (2) (3) (4) – Notes on page 34.

Reconciliation Notes for Slides 31-33

1. Adjusted EBITDA is a non-GAAP financial measure. The Company's leverage ratio (total consolidated debt to Adjusted EBITDA for the trailing four quarters) is, likewise, a non-GAAP financial measure. Management and some members of the investment community utilize Adjusted EBITDA as a financial measure and the leverage ratio as a liquidity measure on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating Adjusted EBITDA, the reader should be aware that in the future HealthSouth may incur expenses similar to the adjustments set forth.
2. Per share amounts for each period presented are based on diluted weighted average shares outstanding unless the amounts are antidilutive, in which case the per share amount is calculated using the basic share count after subtracting the $6.5 million per quarter dividend on the convertible perpetual preferred stock. The difference in shares between the basic and diluted shares outstanding is primarily related to our convertible perpetual preferred stock.
3. Adjusted EBITDA is a component of our guidance.
4. The dividends related to our convertible perpetual preferred stock must be subtracted from income from continuing operations when calculating basic earnings per share.

Reconciliation of Net Income to Adjusted Income from Continuing Operations and Adjusted EBITDA [(1) (3) (4)]

Prior Year Historical Reporting Reclassified for LTCHs

	2010									
	Q1		Q2		Q3		Q4		Full Year	
(in millions, except per share data)	Total	Per Share	Total	Per Share	Total	Per Share	Total	Per Share	Total	Per Share
Net income	$ 50.5	$ 0.54	$ 57.5	$ 0.62	$ 41.9	$ 0.45	$ 789.9	$ 8.51	$ 939.8	$ 10.13
Income from disc ops, net of tax, attributable to HealthSouth	(1.2)	(0.01)	(3.4)	(0.04)	(3.4)	(0.04)	(1.2)	(0.01)	(9.2)	(0.10)
Net income attributable to noncontrolling interests	(9.8)	(0.11)	(10.2)	(0.11)	(10.1)	(0.11)	(10.7)	(0.12)	(40.8)	(0.44)
Income from continuing operations attributable to HealthSouth	39.5	0.43	43.9	0.47	28.4	0.31	778.0	8.38	889.8	9.59
Gov't, class action, and related settlements	-	-	-	-	0.8	0.01	0.3	0.00	1.1	0.01
Pro fees - acct, tax, and legal	2.9	0.03	5.7	0.06	5.2	0.06	3.4	0.04	17.2	0.19
Loss (gain) on interest rate swaps	4.3	0.05	(0.3)	(0.00)	9.0	0.10	0.3	0.00	13.3	0.14
Adjustment for prior period amounts in tax provision	0.9	0.01	(4.2)	(0.05)	(0.4)	(0.00)	(745.1)	(8.03)	(748.8)	(8.07)
Adjusted income from continuing operations [(1)(3)]	$ 47.6	0.51	$ 45.1	0.49	$ 43.0	0.46	$ 36.9	0.40	$ 172.6	1.86
Adjustment for dilution [(2)]		(0.07)		(0.07)		(0.06)		(0.06)		(0.27)
Adjusted income from continuing operations per diluted share [(2)(3)]		$ 0.44		$ 0.42		$ 0.40		$ 0.34		$ 1.59
Current period amounts in tax provision	1.5		2.9		-		3.6		8.0	
Interest expense and amortization of debt discounts and fees	30.5		30.1		30.8		34.2		125.6	
Depreciation and amortization	17.5		17.8		18.4		19.4		73.1	
	97.1		95.9		92.2		94.1		379.3	
Other adjustments per the Company's Credit Agreement:										
Net noncash loss on disposal of assets	-		0.4		0.1		0.9		1.4	
Loss on early extinguishment of debt	0.3		0.1		-		11.9		12.3	
Stock-based compensation expense	3.8		4.0		3.4		5.2		16.4	
Other	-		-		0.2		-		0.2	
Adjusted EBITDA [(1)(3)(4)]	$ 101.2		$ 100.4		$ 95.9		$ 112.1		$ 409.6	
Weighted average common shares outstanding:										
Basic		92.7		92.8		92.8		92.8		92.8
Diluted		108.0		108.2		108.3		108.8		108.5

(1) (2) (3) (4) – Notes on page 36.

Reconciliation Notes for Slide 35

1. Adjusted income from continuing operations and Adjusted EBITDA are non-GAAP financial measures. The Company's leverage ratio (total consolidated debt to Adjusted EBITDA for the trailing four quarters) is, likewise, a non-GAAP financial measure. Management and some members of the investment community utilize adjusted income from continuing operations as a financial measure and Adjusted EBITDA and the leverage ratio as liquidity measures on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating these adjusted measures, the reader should be aware that in the future HealthSouth may incur expenses similar to the adjustments set forth.
2. Per share amounts for each period presented are based on basic weighted average common shares outstanding for all amounts except adjusted income from continuing operations per diluted share, which is based on diluted weighted average shares outstanding. The difference in shares between the basic and diluted shares outstanding is primarily related to our convertible perpetual preferred stock.
3. Adjusted income from continuing operations per diluted share and Adjusted EBITDA are two components of our historical guidance.
4. The Company's credit agreement allows certain other items to be added to arrive at Adjusted EBITDA, and there may be certain other deductions required.

Adjusted Free Cash Flow

Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow

	Q3		9 Months		Full Year		
(Millions)	2011	2010	2011	2010	2010	2009	2008
Net cash provided by operating activities	$ 53.9	$ 90.8	$ 210.8	$ 263.9	$331.0	$ 406.1	$ 227.2
Impact of discontinued operations	(2.2)	(3.1)	(9.4)	(10.4)	(13.2)	(5.7)	(32.5)
Net cash provided by operating activities of continuing operations	51.7	87.7	201.4	253.5	317.8	400.4	194.7
Capital expenditures for maintenance [1]	(12.8)	(11.8)	(35.1)	(24.6)	(37.9)	(33.2)	(41.5)
Net settlements on interest rate swaps [2]	-	(10.6)	(10.9)	(33.7)	(44.7)	(42.2)	(20.7)
Dividends paid on convertible perpetual preferred stock	(6.5)	(6.5)	(19.5)	(19.5)	(26.0)	(26.0)	(26.0)
Distributions paid to noncontrolling interests of consolidated affiliates	(9.4)	(8.0)	(31.6)	(26.3)	(34.4)	(32.6)	(33.4)
Non-recurring items:							
UBS Settlement proceeds, less fees to derivative plaintiffs' attorneys	-	-	-	-	-	(73.8)	-
Net premium paid (received) on bond issuance/redemption	8.9	-	22.8	-	-	-	-
Cash paid for professional fees - accounting, tax and legal	4.0	5.2	16.2	13.8	17.2	15.3	18.2
Cash paid for government, class action and related settlements	-	-	7.7	0.8	2.9	11.2	7.4
Income tax refunds related to prior periods	(3.5)	(2.2)	(6.9)	(11.9)	(13.5)	(63.7)	(89.4)
Adjusted free cash flow	**$ 32.4**	**$ 53.8**	**$ 144.1**	**$ 152.1**	**$ 181.4**	**$ 155.4**	**$ 9.3**

(1) Maintenance capital expenditures are expected to be $10 to $15 million higher in 2011 than in 2010.
(2) Final swap payment of $10.9 million was made in March 2011.

HEALTHSOUTH

Net Cash Provided by Operating Activities

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA

	Q3		9 Months		Full Year		
(Millions)	2011	2010	2011	2010	2010	2009	2008
Net cash provided by operating activities	$ 53.9	$ 90.8	$210.8	$ 263.9	$ 331.0	$406.1	$227.2
Provision for doubtful accounts	(5.1)	(3.7)	(14.9)	(14.8)	(16.4)	(30.7)	(23.0)
Professional fees—accounting, tax, and legal	4.0	5.2	16.2	13.8	17.2	8.8	44.4
Interest expense and amortization of debt discounts	26.3	30.8	96.3	91.4	125.6	125.7	159.3
UBS Settlement proceeds, gross	-	-	-	-	-	(100.0)	-
Equity in net income of nonconsolidated affiliates	3.1	2.3	8.8	7.5	10.1	4.6	10.6
Net income attributable to noncontrolling interests in continuing operations	(11.4)	(10.3)	(34.5)	(30.3)	(40.9)	(33.3)	(29.8)
Amortization of debt discounts and fees	(1.0)	(1.7)	(3.3)	(5.1)	(6.3)	(6.6)	(6.5)
Distributions from nonconsolidated affiliates	(4.2)	(1.4)	(9.7)	(4.7)	(8.1)	(8.6)	(10.9)
Current portion of income tax expense (benefit)	(0.1)	(0.7)	(1.5)	(1.7)	2.9	(7.0)	(72.8)
Change in assets and liabilities	38.6	(12.6)	68.1	(14.1)	2.7	(2.0)	50.6
Net premium paid (received) on bond issuance/redemption	8.9	-	22.8	-	-	-	-
Change in government, class action and related settlements liability	-	-	(6.5)	0.8	2.9	11.2	7.4
Cash (provided by) used in operating activities of discontinued operations	(2.2)	(3.1)	(9.4)	(10.4)	(13.2)	(5.7)	(32.5)
Other	(0.3)	0.3	0.1	1.2	2.1	1.2	(1.4)
Adjusted EBITDA	$ 110.5	$ 95.9	$343.3	$ 297.5	$ 409.6	$363.7	$322.6

HEALTHSOUTH